Immunomodulatory properties of CD38 antibodies and their effect on anticancer efficacy in multiple myeloma

BACKGROUND: CD38 has been established as an important therapeutic target for multiple myeloma (MM), for which two CD38 antibodies are currently approved—daratumumab and isatuximab. CD38 is an ectoenzyme that degrades NAD and its precursors and is involved in the production of adenosine and other met...

Descripción completa

Detalles Bibliográficos
Autores principales: Bisht, Kamlesh, Fukao, Taro, Chiron, Marielle, Richardson, Paul, Atanackovic, Djordje, Chini, Eduardo, Chng, Wee Joo, Van De Velde, Helgi, Malavasi, Fabio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
REVIEW
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10652336/
https://www.ncbi.nlm.nih.gov/pubmed/37840445
http://dx.doi.org/10.1002/cam4.6619

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10652336/
https://www.ncbi.nlm.nih.gov/pubmed/37840445
http://dx.doi.org/10.1002/cam4.6619

Ejemplares similares